BRAF and melanoma: In melanoma, this pathway is particularly active because of a commonly found activating mutation in B-Raf V600E (Davies et al., 2002) that bypasses Ras and the negative feedback that normally restrains MEK/Erk activity (Logue and Morrison, 2012).